Investors

Webcast
Geron 2018 Annual Meeting of Stockholders
May 15, 2018 at 4:00 PM PDT
Webcast Presentation

Geron 2018 Annual Meeting of Stockholders
May 15, 2018 at 4:00 PM PDT

Corporate Profile

Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imetelstat is currently being tested in two clinical trials: IMbark™, a Phase 2 trial in myelofibrosis (MF) and IMerge™, a Phase 2/3 trial in myelodysplastic syndromes (MDS). These clinical trials are being conducted by Janssen Biotech, Inc., under a collaboration and license agreement, in which Janssen were granted the exclusive rights to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses.

Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using Geron’s proprietary nucleic acid chemistry, imetelstat was designed as an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. Early clinical data, including molecular responses in essential thrombocythemia (ET) and remissions, including reversal of bone marrow fibrosis in MF, suggest imetelstat may have disease-modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases.

Recent News

Date Title and Summary  
Toggle Summary Updated Results from Geron's Imetelstat Phase 2 Proof-of-Concept Trial in Essential Thrombocythemia Presented at the European Hematology Association Congress
Data from an Additional Six Months of Imetelstat Treatment and Follow-Up since ASH 2012 Imetelstat Continues to be Well Tolerated with No New Safety Signals Reported; No Patients Have Discontinued Treatment Due to Drug-Related Adverse Events Hematologic and Molecular Responses are Maintained MENLO
Toggle Summary University of Edinburgh Human Embryonic Stem Cell Program Awarded UK Grant Funding
MENLO PARK, Calif., May 6, 2008 – Geron Corporation (Nasdaq: GERN) announced today two grant awards to the University of Edinburgh from the UK Stem Cell Foundation, with funding from the Medical Research Council and Scottish Enterprise. The awards, totalling £3.6 million (US$7.2 million) over two
Toggle Summary Unique Structure of Geron´s Telomerase Inhibitor Drug Promotes Anti-Tumor, Anti-Metastatic Activity in Lung Cancer Cells
MENLO PARK, Calif., Feb. 15, 2007 – Geron Corporation (Nasdaq: GERN) today announced the publication of preclinical data that show specific structural elements of GRN163L contribute to its unique anti–tumor and anti–metastatic activity. Published in Cancer Research (2007; 67: 1121–29), the studies

Upcoming Events

More >>
There are currently no events to display.

Corporate Presentation

Documents

Stock Information

Copyright Nasdaq. Minimum 15 minutes delayed.

Contact Information

CG Capital
877-889-1972

investor@geron.com